Clinical Trial Update: Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma [Phase 2]

View source ↗

Summary

This update reports on a Phase 2 trial of ABX-EGF (panitumumab) in patients with metastatic colorectal cancer; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ABX-EGF (panitumumab)

Snippet

Sponsor: Amgen | Conditions: Colorectal Cancer, Carcinoma | Phase 2 | Status: COMPLETED